Actively Recruiting
Role of KATP Channel Loss in Type 2 Diabetes
Led by Washington University School of Medicine · Updated on 2025-07-04
40
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.
CONDITIONS
Official Title
Role of KATP Channel Loss in Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years
- Lean normoglycemic group: BMI 18.5 to less than 25.0 kg/m², fasting plasma glucose under 95 mg/dl, 2-hour oral glucose tolerance test plasma glucose 140 mg/dl or less, and hemoglobin A1C 5.6% or less
- Obesity normoglycemic group: BMI 30 to less than 50 kg/m², fasting plasma glucose under 95 mg/dl, 2-hour oral glucose tolerance test plasma glucose 140 mg/dl or less, and hemoglobin A1C 5.6% or less
- Obesity impaired fasting glucose group: BMI 30 to less than 50 kg/m², fasting plasma glucose 100-125 mg/dl, 2-hour oral glucose tolerance test plasma glucose under 200 mg/dl
- Obesity type 2 diabetes group: BMI 30 to less than 50 kg/m², hemoglobin A1C 6.5-9.5%, fasting plasma glucose 126 mg/dl or more, 2-hour oral glucose tolerance test plasma glucose 200 mg/dl or more and/or medical history of type 2 diabetes and currently using anti-diabetic medications
You will not qualify if you...
- Using insulin therapy at more than 0.5 units/kg/day
- Any change in diabetes medication in the previous 3 months
- Unstable weight with more than 2% change in the last 2 months before the study
- Significant organ dysfunction or disease other than obesity and type 2 diabetes
- Regular use of tobacco products
- Excessive alcohol consumption (3 or more drinks/day for men, 2 or more drinks/day for women)
- Use of medications that affect study outcomes or increase procedure risks and that cannot be paused during the study
- Anemia with hemoglobin less than 10.0 g/dL
- Pregnant or breastfeeding
- Unable or unwilling to follow the study protocol or deemed inappropriate by the research team, including non-compliance with visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University in St. Louis
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
K
Kyle Timmons
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here